PFE Pfizer Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
PFE Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Drug Manufacturers - General
Current Price
Live
$25.65
Analyst Target
$28.66
+11.7%
Upside
52W High
$27.69
52W Low
$20.92
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 17, 2026
Market cap
$145.84B
P/E
14.91
ROE
10.6%
Profit margin
15.7%
Debt/Equity
0.67
Dividend yield
6.64%
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
68%
Analysis Accuracy
Pfizer's deterministic health score is weak with a Piotroski F-Score of 4/9, indicating marginal financial stability. Despite strong profitability metrics like high gross and operating margins, the company faces declining revenue and earnings, reflected in negative YoY growth. The stock trades near its Graham Number ($25.13 vs. $25.65), suggesting fair value, but the extremely high payout ratio (99.42%) raises sustainability concerns. Analysts recommend a buy with a target of $28.66, yet technical trend and insider sentiment are bearish, offsetting upside potential.
Key Strengths
High gross margin (74.81%) indicating strong pricing power and cost control
Attractive dividend yield of 6.64%, among the highest in the sector
Forward P/E of 8.60 is significantly below sector average, suggesting value
Strong quarterly earnings surprise streak with 3 out of last 4 beats and double-digit average surprises
Debt/Equity of 0.67 is below sector average, reflecting conservative leverage
Key Risks
Piotroski F-Score of 4 indicates weak financial health and operational instability
Revenue and earnings declining YoY (-5.90% and -21.30%) signal fundamental headwinds
Payout ratio of 99.42% threatens dividend sustainability despite current yield
Technical trend score of 0/100 indicates strong bearish momentum
Insider sentiment at 40/100 suggests lack of confidence from company executives
AI Fair Value Estimate
Based on comprehensive analysis
$25.13
-2.0% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
53
Moderate
72
38
56
42
58
AI Verdict
Neutral with value appeal but structural risks
Key drivers: Low Piotroski score limiting health rating, High dividend yield supporting income appeal, Forward P/E discount to sector, Negative growth trends offsetting value metrics, Analyst target implying 11.7% upside
Confidence
70%
Value
72/100
Ref P/E, PEG, Graham Number
Positives
- Current price ($25.65) very close to Graham Number ($25.13)
- Forward P/E of 8.60 well below sector average of 249.85
- Price/Book of 1.57 is reasonable for healthcare
Watchpoints
- Intrinsic value formula suggests only $12.04, indicating potential overvaluation on growth basis
Future
38/100
Ref Growth rates
Positives
- Recent Q/Q EPS growth of +70.6% shows potential rebound
- Analyst target price implies upside
Watchpoints
- Revenue Growth (YoY): -5.90%
- Earnings Growth (YoY): -21.30%
- Q/Q Earnings Growth: -20.70%
Past
56/100
Ref Historical trends
Positives
- Consistent earnings beats over last 4 quarters (avg +38.52% surprise)
- History of positive earnings surprises in 2024 and 2025
Watchpoints
- 1Y price return of +3.8% lags sector
- 3Y change of -33.8% reflects prolonged underperformance
Health
42/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current Ratio of 1.28 indicates short-term liquidity adequacy
- Debt/Equity of 0.67 is manageable
Watchpoints
- Piotroski F-Score of 4/9 indicates weak financial health
- Quick Ratio of 0.90 is below 1.0, signaling potential liquidity stress
- Altman Z-Score missing, creating uncertainty in bankruptcy risk assessment
Dividend
58/100
Ref Yield, Payout
Positives
- Dividend yield of 6.64% is highly attractive in current market
- Dividend rate of $1.72 is stable
Watchpoints
- Payout ratio of 99.42% is dangerously high and unsustainable long-term
- No 5-year average yield data to confirm consistency
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$25.65
Analyst Target
$28.66
Upside/Downside
+11.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PFE and closest competitors.
Updated 2026-01-16
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PFE
Pfizer Inc.
Primary
|
-10.9% | -33.8% | +3.8% | +8.5% | +2.4% | +0.7% |
|
SYK
Stryker Corporation
Peer
|
+58.2% | +46.1% | -3.8% | -6.1% | +3.4% | -1.0% |
|
BSX
Boston Scientific Corporation
Peer
|
+151.5% | +101.8% | -9.0% | -12.8% | -3.8% | +5.0% |
|
GILD
Gilead Sciences, Inc.
Peer
|
+125.7% | +62.5% | +40.1% | +17.0% | +2.9% | +3.1% |
|
DHR
Danaher Corporation
Peer
|
+15.2% | -1.7% | -1.8% | +24.6% | +6.2% | -1.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
14.91
Forward P/E
8.6
PEG Ratio
N/A
P/B Ratio
1.57
P/S Ratio
2.32
EV/Revenue
3.08
EV/EBITDA
7.89
Market Cap
$145.84B
Profitability
Profit margins and return metrics
Profit Margin
15.65%
Operating Margin
35.28%
Gross Margin
74.81%
ROE
10.6%
ROA
5.19%
Growth
Revenue and earnings growth rates
Revenue Growth
-5.9%
Earnings Growth
-21.3%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-20.7%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.67
Moderate
Current Ratio
1.28
Good
Quick Ratio
0.9
Poor
Cash/Share
$2.64
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-03
$N/A
2025-11-04
$0.87
+37.4% surprise
2025-08-05
$0.51
+41.6% surprise
2025-04-29
$0.92
+36.5% surprise
Healthcare Sector Comparison
Comparing PFE against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
P/E Ratio
14.91
This Stock
vs
164.56
Sector Avg
-90.9%
(Discount)
Return on Equity (ROE)
10.6%
This Stock
vs
-52.77%
Sector Avg
-120.1%
(Below Avg)
Profit Margin
15.65%
This Stock
vs
-20.78%
Sector Avg
-175.4%
(Weaker)
Debt to Equity
0.67
This Stock
vs
6.16
Sector Avg
-89.2%
(Less Debt)
Revenue Growth
-5.9%
This Stock
vs
137.39%
Sector Avg
-104.3%
(Slower)
Current Ratio
1.28
This Stock
vs
3.36
Sector Avg
-61.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PFE
Pfizer Inc.
|
NEUTRAL | $145.84B | 14.91 | 10.6% | 15.7% | $25.65 | |
|
SYK
Stryker Corporation
|
BEARISH | $139.12B | 47.8 | 14.0% | 12.1% | $363.78 | |
|
BSX
Boston Scientific Corporation
|
NEUTRAL | $137.19B | 48.69 | 12.5% | 14.4% | $92.51 | |
|
GILD
Gilead Sciences, Inc.
|
NEUTRAL | $154.99B | 19.34 | 40.7% | 27.9% | $124.91 | |
|
DHR
Danaher Corporation
|
NEUTRAL | $168.98B | 48.46 | 6.8% | 14.4% | $235.99 |
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
24 analysts
Morgan Stanley
2025-12-17
Equal-Weight
Equal-Weight
B of A Securities
2025-12-15
Neutral
Neutral
Morgan Stanley
2025-12-12
Equal-Weight
Equal-Weight
Guggenheim
2025-11-24
Buy
Buy
Morgan Stanley
2025-10-10
Equal-Weight
Equal-Weight
B of A Securities
2025-10-03
Neutral
Neutral
Citigroup
2025-08-06
Neutral
Neutral
Morgan Stanley
2025-08-06
Equal-Weight
Equal-Weight
B of A Securities
2025-08-06
Neutral
Neutral
Past News Coverage
Recent headlines mentioning PFE from our newsroom.
Newest → oldest
No matching news yet.